Aktienanalyse zu LeMaitre Vascular Inc (LMAT)LMATLeMaitre Vascular Inc

LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. It develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which are used in open vascular surgery and dialysis access. It offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold globally in the United States, Europe, Canada and Asia Pacific. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

LeMaitre Vascular Inc is currently priced at $80.82, which is below the average analyst target of $106.75. However, the stock has an RSI of 45.66, indicating it is nearing oversold territory, but the recent 25.32% drop following the last earnings report suggests caution. The forward P/E ratio of 25.58 indicates it is relatively expensive compared to its growth potential, which has been revised down to 11%. Therefore, while there is potential for recovery, the recent performance and analyst caution suggest holding rather than buying at this time.

8 analysts cover LMAT: 2 rate it Buy, 6 Hold and 0 Sell. The average price target is 105.20.